Literature DB >> 20211620

Uncoupling JAK3 activation induces apoptosis in human lymphoid cancer cells via regulating critical survival pathways.

Zsuzsanna S Nagy1, Jeremy A Ross, Georgialina Rodriguez, Julia Bader, Jonathan Dimmock, Robert A Kirken.   

Abstract

In the current work, we report that specific inhibition of Janus tyrosine kinase (JAK3) via NC1153 induces apoptosis of certain leukemia/lymphoma cell lines. Affymetrix microarray profiling following NC1153 treatment unveiled JAK3 dependent survival modulating pathways (p53, TGF-beta, TNFR and ER stress) in Kit225 cells. IL-2 responsive NC1153 target genes were regulated in human JAK3 positive, but not in JAK3 negative lymphoid tumor cells. Moreover, primary lymphoma samples revealed that a number of these genes were reciprocally regulated during disease progression and JAK3 inhibition suggesting that downstream targets of JAK3 could be exploited in the development of novel cancer treatment regimes. Copyright 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20211620      PMCID: PMC2854231          DOI: 10.1016/j.febslet.2010.02.071

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  28 in total

Review 1.  IL-9 and its receptor: from signal transduction to tumorigenesis.

Authors:  Laurent Knoops; Jean-Christophe Renauld
Journal:  Growth Factors       Date:  2004-12       Impact factor: 2.511

2.  BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks.

Authors:  Steven Maere; Karel Heymans; Martin Kuiper
Journal:  Bioinformatics       Date:  2005-06-21       Impact factor: 6.937

3.  Activation status of the JAK/STAT3 pathway in mantle cell lymphoma.

Authors:  Marwan A Yared; Joseph D Khoury; L Jeffrey Medeiros; George Z Rassidakis; Raymond Lai
Journal:  Arch Pathol Lab Med       Date:  2005-08       Impact factor: 5.534

4.  The Mannich base NC1153 promotes long-term allograft survival and spares the recipient from multiple toxicities.

Authors:  Stanislaw M Stepkowski; Judy Kao; Mou-Er Wang; Neelam Tejpal; Hemangshu Podder; Lucrezia Furian; Jonathan Dimmock; Amitabh Jha; Umashankar Das; Barry D Kahan; Robert A Kirken
Journal:  J Immunol       Date:  2005-10-01       Impact factor: 5.422

5.  Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells.

Authors:  R A Kirken; R A Erwin; D Taub; W J Murphy; F Behbod; L Wang; F Pericle; W L Farrar
Journal:  J Leukoc Biol       Date:  1999-06       Impact factor: 4.962

6.  Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells.

Authors:  Lin Qiu; Raymond Lai; Quan Lin; Esther Lau; David M Thomazy; Daniel Calame; Richard J Ford; Larry W Kwak; Robert A Kirken; Hesham M Amin
Journal:  Blood       Date:  2006-06-08       Impact factor: 22.113

Review 7.  Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency.

Authors:  J A Johnston; C M Bacon; M C Riedy; J J O'Shea
Journal:  J Leukoc Biol       Date:  1996-10       Impact factor: 4.962

8.  Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant.

Authors:  F J Oliver; G de la Rubia; V Rolli; M C Ruiz-Ruiz; G de Murcia; J M Murcia
Journal:  J Biol Chem       Date:  1998-12-11       Impact factor: 5.157

9.  Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development.

Authors:  S M Russell; N Tayebi; H Nakajima; M C Riedy; J L Roberts; M J Aman; T S Migone; M Noguchi; M L Markert; R H Buckley; J J O'Shea; W J Leonard
Journal:  Science       Date:  1995-11-03       Impact factor: 47.728

Review 10.  The Janus kinases (Jaks).

Authors:  Kunihiro Yamaoka; Pipsa Saharinen; Marko Pesu; Vance E T Holt; Olli Silvennoinen; John J O'Shea
Journal:  Genome Biol       Date:  2004-11-30       Impact factor: 13.583

View more
  2 in total

1.  Transforming Mutations of Jak3 (A573V and M511I) Show Differential Sensitivity to Selective Jak3 Inhibitors.

Authors:  G Steven Martinez; Jeremy A Ross; Robert A Kirken
Journal:  Clin Cancer Drugs       Date:  2016

2.  Genome wide mapping reveals PDE4B as an IL-2 induced STAT5 target gene in activated human PBMCs and lymphoid cancer cells.

Authors:  Zsuzsanna S Nagy; Jeremy A Ross; Georgialina Rodriguez; Balint L Balint; Lajos Szeles; Laszlo Nagy; Robert A Kirken
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.